Confirmation that a compound inhibits the intended target (drug target validation) and the identification of undesirable secondary effects are among the main challenges in developing new drugs.

Therefore, drug targets that act in the brain, specifically on the central component of the trigeminovascular system, the TCC, would seem to be ideally placed to modulate this nociceptive pathway ...

However, we believe this novel drug target has potential in the treatment of other neurodegenerative diseases beyond NPC that are still lacking disease-modifying therapies. With this in mind ...